Form 4: TriSalus Life Sciences CFO Acquires Shares

David Patience, Chief Financial Officer of TriSalus Life Sciences, Inc., reported the acquisition of 7,100 shares of common stock.

Summary

• David Patience, Chief Financial Officer of TriSalus Life Sciences, Inc. (TLSI), acquired 7,100 shares of common stock on May 15, 2026.
• The acquisition was made at a price of $2.43 per share.
• Following this transaction, Mr. Patience beneficially owns 275,757 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing due to the CFO's direct purchase of company stock, signaling confidence, though it does not provide broader financial performance data.

Positives

• The Chief Financial Officer's acquisition of company stock can be interpreted as a positive signal of confidence in the company's future prospects.
• The purchase of 7,100 shares indicates a direct investment by a key executive.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider stock purchases, particularly by a CFO, are often viewed by the market as a sign of management's belief in the company's intrinsic value and future growth potential. This action by the CFO of TriSalus Life Sciences, Inc. could be interpreted as a positive indicator within the life sciences sector, which is often driven by investor confidence in innovation and financial stability.

Stakeholder Impact

• Shareholders may view the CFO's purchase positively, interpreting it as a sign of confidence in the company's future performance.
• Employees may also see this as a positive indicator of leadership's belief in the company's stability and growth.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, Form 4, Insider Trading, Stock Acquisition, David Patience, Chief Financial Officer